Poonawalla IB, Bowe AT, Tindal MC, Meah YA, Schwab P. A real-world comparison of cardiovascular, medical and costs outcomes in new users of SGLT2 inhibitors versus GLP-1 agonists. Diabetes Res Clin Pract. 2021 May;175:108800. doi: 10.1016/j.diabres.2021.108800
Schwab P, Louder A, Li Y, Mallick R, Bays H. Cholesterol treatment patterns and cardiovascular clinical outcomes associated with colesevelam HCl and ezetimibe. Drugs Aging. 2014 Sep;31(9):683-94. doi: 10.1007/s40266-014-0200-6
Schwab PE, Saundankar V, Bouchard J, Moretz C, Baltz J. Delayed treatment modifications for patients with type 2 diabetes mellitus with very poor glycemic control. Poster presented at the 2014 ISPOR 19th Annual International Meeting; May 31, 2014. Montreal, Canada. [abstract] Value Health. 2014 May; 17(3).
Seiffert R, Schwab PE, Slabaugh L, Rasca P. Descriptive analysis of prevalence and cost of bleeds and joint complications in factor product users. Poster presented at the 2014 Academy of Managed Care Pharmacy's 26th Annual Meeting & Expo; April 1, 2014. Tampa, FL.
James T, Ward M, Schwab PE, Slabaugh L, Saverno K, Anderson C. Cost-effectiveness analysis of triple and dual therapies in patients with chronic hepatitis C genotype 1 infections. Poster presented at the 2014 Academy of Managed Care Pharmacy's 26th Annual Meeting & Expo; April 1, 2014. Tampa, FL.